Vaxart saw the highest growth of 0.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.32% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Vaxart‘s patent filings and grants. Buy the databook here.
Vaxart has been focused on protecting inventions in Denmark(DK) with one publication in Q2 2024
The Denmark(DK) Patent Office dominates the patent filings with nearly 50% of filings. The Denmark(DK), and European Patent Office(EPO) patent Office are among the top ten patent offices where Vaxart is filings its patents..
Gritstone Bio could be the strongest competitor for Vaxart
For comprehensive analysis of Vaxart's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.